Showing 4161-4170 of 5304 results for "".
- Burt's Bees Natural Retinol Alternative Works Well in Sensitive Skinhttps://practicaldermatology.com/news/burts-bees-natural-retinol-alternative-works-well-in-sensitive-skin/2460430/Three new studies from Burt’s Bees highlight the safety and efficacy of Bakuchiol, a natural retinol alternative, as well as a new facial oil and lip balm. The findings were presented online at the American Academy of Dermatology (AAD
- Johnson & Johnson Consumer Health Research Sheds Light on the Development of the Skin Microbiomehttps://practicaldermatology.com/news/johnson-johnson-consumer-health-research-sheds-light-on-the-development-of-the-skin-microbiome/2460428/New Johnson & Johnson Consumer Health research provides key insights into how the infant microbiome develops from birth to childhood. The findings, based on 10 years of data, were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020.
- Sciton Unveils mJOULE Platform Featuring BBL HERO And MOXIhttps://practicaldermatology.com/news/sciton-unveils-mjoule-platform-featuring-bbl-hero-and-moxi/2460420/Sciton Inc. is rolling out their mJOULE dual-wavelength platform which includes a new fractional treatment, MOXI, and BBL HERO. MOXI delivers non-ablative laser energy to revitalize skin and BroadBand Light HERO (High Energy Rapid Output) allows practitioners to treat the entire body wi
- New from Obagi: Two Sunscreens and a Hydrating Serumhttps://practicaldermatology.com/news/new-from-obagi-two-sunscreens-and-a-hydrating-serum/2460415/Obagi is launching two new Physical Defense Sunscreens and Daily Hydro-Drops. The new SUZANOBAGIMD Physical Defense Sunscreens, available in broad-spectrum SPF 40 and tinted SPF 50, defend against five light sources, including high energy visible light, or blue light, visible light
- Promising Data from Dermavant's Phase 2b Study of Tapinarof in Psoriasishttps://practicaldermatology.com/news/promising-data-from-dermavants-phase-2b-study-of-tapinorof-in-psoriasis/2460405/Patients treated with once daily tapinarof 1% demonstrated improvement in PASI75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase
- FDA Approves Dupixent for Children Aged 6 to 11 Years with Moderate-to-Severe ADhttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-aged-6-to-11-years-with-moderate-to-severe-ad/2460404/The US Food and Drug Administration (FDA) gave its nod to Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Dupixent comes in two doses, prescribed based on weight (300 mg every four weeks for children ≥15 to <30 kg and 200 mg eve
- Crayola Announces New "Colors of the World" Crayons To Help Advance "Skinclusion"https://practicaldermatology.com/news/crayola-announces-new-colors-of-the-world-crayons-to-help-advance-skinclusion/2460402/Crayola is launching Colors of the World crayons—24 new crayons designed to represent more than 40 global skin tones across the world. The crayon packs feature side panels that serve as color references. Each crayon is wrapped in a gradient skin tone label with the color
- Hoth Therapeutics Obtains Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/hoth-therapeutics-obtains-full-licensing-rights-for-biolexa-platform-atopic-dermatitis-treatment/2460397/Hoth Therapeutics, Inc. has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. This agreement serves as an extension to the previo
- Galderma: Patients Treated with Dysport Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Yearhttps://practicaldermatology.com/news/galderma-patients-treated-with-dysport-achieved-high-levels-of-satisfaction-and-natural-looking-results-with-two-treatments-per-year/2460391/Topline results of DREAM (Dysport Real-world Evaluation and Measured satisfaction study), a clinical study of Dysport (abobotulinumtoxinA) for injection, showed that 95 percent of patients treated with Dysport achieved high levels of satisfaction with two treat
- May Is Ichthyosis Awareness Monthhttps://practicaldermatology.com/news/may-is-ichthyosis-awareness-month/2460390/May is Ichthyosis Awareness Month, and Timber Pharmaceuticals, LLC is highlighting the efforts of the